Section Arrow
VNDA.NASDAQ
- Vanda Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/21 16:52 EDT
After Hours
Last
 4.75
+0.09 (+1.93%)
Bid
4.62
Ask
4.9
High 4.75 
Low 4.63 
Volume 5116 
Regular Hours
Last
 4.66
-0.12 (-2.51%)
Day High 
4.83 
Prev. Close
4.78 
1-M High
5.12 
Volume 
461.92K 
Bid
4.62
Ask
4.9
Day Low
4.645 
Open
4.77 
1-M Low
4.3801 
Market Cap 
281.71M 
Currency USD 
P/E 126.25 
%Yield -- 
10-SMA 4.87 
20-SMA 4.78 
50-SMA 4.52 
52-W High 6.365 
52-W Low 3.8092 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.76/0.03
Enterprise Value
289.80M
Balance Sheet
Book Value Per Share
8.68
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
198.77M
Operating Revenue Per Share
4.04
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
After Hours 0.1184 -0.011 -8.50%
NCNANuCana plc0.051+0.0033+6.92%-- 
After Hours 0.0521 +0.0011 +2.16%
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
After Hours 1.11 -0.01 -0.89%
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
After Hours 2.67 -0.03 -1.11%
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
After Hours 6.3996 -0.0004 -0.01%
Quotes are at least 15-min delayed:2025/07/21 16:52 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.